JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE 300 MG — DIN 02519461
TENOFOVIR DISOPROXIL FUMARATE : 300 MG EMTRICITABINE : 200 MG EFAVIRENZ : 600 MG · JAMP PHARMA CORPORATION · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE?
JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE 300 MG contains TENOFOVIR DISOPROXIL FUMARATE : 300 MG EMTRICITABINE : 200 MG EFAVIRENZ : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02519461, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE used for?
JAMP Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (efavirenz [EFV]/emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Emtricitabine, Tenofovir Disoproxil And Efavirenz in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Emtricitabine, Tenofovir Disoproxil And Efavirenz, across 9 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 1 | 1 | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | Sourceable in Canada |
| GILEAD SCIENCES, LLC | 1 | 0 | ATRIPLA | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Emtricitabine, Tenofovir Disoproxil And Efavirenz |
|---|---|
| ATC code | J05AR06 |
| AHFS class | 08:18.08.16 ; 08:18.08.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02519461 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2519461 |
| Brand name | JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE |
| Generic / active ingredient | TENOFOVIR DISOPROXIL FUMARATE : 300 MG EMTRICITABINE : 200 MG EFAVIRENZ : 600 MG |
| Market authorization holder | JAMP PHARMA CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | J05AR06 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AR |
| Current status | MARKETED |
| Status date | 14-Dec-2022 |
| Original market date | 2022-12-14 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 200 MG | TABLET | APOTEX INC | MARKETED | 02468247 |
| AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 200 MG | TABLET | AURO PHARMA INC | MARKETED | 02478404 |
| MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | 300 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02461412 |
| TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 200 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02393549 |
| ATRIPLA | 200 MG | TABLET | GILEAD SCIENCES, LLC | CANCELLED POST MARKET | 02300699 |
| PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | 600 MG | TABLET | PHARMASCIENCE INC | DORMANT | 02487284 |
| RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 300 MG | TABLET | LABORATOIRE RIVA INC. | CANCELLED POST MARKET | 02518716 |
| SANDOZ EFAVIRENZ/EMTRICITABINE/TENOFOVIR | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02484676 |
2 · Same class — other molecules in ATC J05AR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil And Emtricitabine | AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE · APO-EMTRICITABINE-TENOFOVIR · AURO-EMTRICITABINE-TENOFOVIR · JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +6 more | 10 | 9 | Yes |
| Emtricitabine, Tenofovir Disoproxil And Efavirenz | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATRIPLA · AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +5 more | 9 | 5 | Yes |
| Lamivudine And Abacavir | APO-ABACAVIR-LAMIVUDINE · APO-ABACAVIR-LAMIVUDINE TABLETS · AURO-ABACAVIR/LAMIVUDINE · JAMP ABACAVIR / LAMIVUDINE · +5 more | 9 | 4 | Yes |
| Zidovudine And Lamivudine | APO-LAMIVUDINE-ZIDOVUDINE · AURO-LAMIVUDINE/ZIDOVUDINE · COMBIVIR · JAMP LAMIVUDINE / ZIDOVUDINE · +1 more | 5 | 3 | Yes |
| Lopinavir And Ritonavir | KALETRA | 4 | 3 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Bictegravir | BIKTARVY | 2 | 2 | Yes |
| Emtricitabine And Tenofovir Alafenamide | DESCOVY | 2 | 2 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Rilpivirine | ODEFSEY | 1 | 1 | Yes |
| Darunavir And Cobicistat | PREZCOBIX | 1 | 1 | Yes |
| Emtricitabine, Tenofovir Alafenamide, Elvitegravir And Cobicistat | GENVOYA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.